Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Goff, Peter H ^a   Eggink, Dirk ^a   Seibert, Christopher W ^a   Hai, Rong ^a   Martínez Gil, Luis ^a   Krammer, Florian ^a   Palese, Peter ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADDAVAX; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN M; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; POLYINOSINIC POLYCYTIDYLIC ACID; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGLOBULIN PRODUCTION; INFECTION RESISTANCE; INFLUENZA A; INFLUENZA VIRUS A; MOUSE; NANOEMULSION; NONHUMAN; PROTEIN INDUCTION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SENDAI VIRUS; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; DOGS; EMULSIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEK293 CELLS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNIZATION; INFLUENZA A VIRUS; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED BALB C; NUCLEIC ACID CONFORMATION; ORTHOMYXOVIRIDAE INFECTIONS; POLY I-C; POLYSORBATES; RECOMBINANT FUSION PROTEINS; RNA, VIRAL; SENDAI VIRUS; SQUALENE;

EID: 84890554900     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079194     Document Type: Article

References (25)

1. Smith GJD, Bahl J, Vijaykrishna D, Zhang J, Poon LLM et al. (2009) Dating the emergence of pandemic influenza viruses. Proc Natl Acad Sci U S A 106: 11709-11712. doi:10.1073/pnas.0904991106. PubMed: 19597152.
2. Palese P, Shaw M, Wright P, Neumann G, Kawaoka Y (2006) Orthomyxoviridae (Chapters 47 & 48). In: D KnipeP Howley, Fields Virology . Philadelphia: Lippincott Williams & Wilkins.
3. Schaffner W (2006) The Impact of "Mismatched Strains" on Influenza Vaccinations. US Infectious Diseases: 28-30.
4. Ohmit SE, Petrie JG, Malosh RE, Cowling BJ, Thompson MG et al. (2013) Influenza Vaccine Effectiveness in the Community and the Household. Clin Infect Dis, 56: 1-7. doi:10.1093/cid/cit060. PubMed: 23413420.
5. Cox RJ (2013) Correlates of protection to influenza virus, where do we go from here? Hum Vaccines Immunotherapies 9: 405-408. doi: 10.4161/hv.22908. PubMed: 23291930.
6. Ekiert DC, Wilson IA (2012) Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Current Opinion Virology 2: 134-141. doi:10.1016/j.coviro.2012.02.005. PubMed: 22482710.
7. Hai R, Krammer F, Tan GS, Pica N, Eggink D et al. (2012) Influenza viruses expressing chimeric hemagglutinins: Globular head and stalk domains derived from different subtypes. J Virol 86: 5774-5781. doi: 10.1128/JVI.00137-12. PubMed: 22398287.
8. Pica N, Hai R, Krammer F, Wang TT, Maamary J et al. (2012) Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A 109: 2573-2578. doi:10.1073/pnas.1200039109. PubMed: 22308500.
9. Krammer F, Pica N, Hai R, Margine I, Palese P (2013) Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87: 6542-6550. doi:10.1128/JVI.00641-13. PubMed: 23576508.
10. Clegg CH, Roque R, Van Hoeven N, Perrone L, Baldwin SL et al. (2012) Adjuvant solution for pandemic influenza vaccine production. Proc Natl Acad Sci U S A 109: 17585-17590. doi:10.1073/pnas. 1207308109. PubMed: 23045649.
11. Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F et al. (2011) MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 3: 85ra48. doi:10.1126/scitranslmed.3002336. PubMed: 21632986.
12. Martínez-Gil L, Goff PH, Hai R, García-Sastre A, Shaw ML et al. (2013) A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. J Virol 87: 1290-1300. doi:10.1128/JVI.02338-12. PubMed: 23175362.
13. Krammer F, Margine I, Tan GS, Pica N, Krause JC et al. (2012) A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLOS ONE 7: e43603. doi:10.1371/journal.pone.0043603. PubMed: 22928001.
14. Tan GS, Krammer F, Eggink D, Kongchanagul A, Moran TM et al. (2012) A pan-h1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol 86: 6179-6188. doi:10.1128/JVI.00469-12. PubMed: 22491456.
15. Caproni E, Tritto E, Cortese M, Muzzi A, Mosca F et al. (2012) MF59 and Pam3CSK4 Boost Adaptive Responses to Influenza Subunit Vaccine through an IFN Type I-Independent Mechanism of Action. J Immunol 188: 3088-3098. doi:10.4049/jimmunol.1101764. PubMed: 22351935.
16. Aoshi T, Koyama S, Kobiyama K, Akira S, Ishii KJ (2011) Innate and adaptive immune responses to viral infection and vaccination. Current Opinion in Virology 1: 226-232. doi:10.1016/j.coviro.2011.07.002. PubMed: 22440781.
17. Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G et al. (2013) Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 190: 1837-1848. doi:10.4049/jimmunol.1201574. PubMed: 23319732.
18. Terajima M, Cruz J, Co MDT, Lee J-H, Kaur K et al. (2011) Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies. J Virol 85: 13463-13467. doi:10.1128/JVI.05193-11. PubMed: 21994454.
19. Seibert CW, Rahmat S, Krause JC, Eggink D, Albrecht RA et al. (2013) Recombinant IgA is sufficient to prevent influenza virus transmission in Guinea pigs. J Virol 87: 7793-7804. doi:10.1128/JVI.00979-13. PubMed: 23698296.
20. Renegar KB, Small PA, Boykins LG, Wright PF (2004) Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173: 1978-1986. PubMed: 15265932.
21. Renegar KB, Small PA (1991) Passive transfer of local immunity to influenza virus infection by IgA antibody. J Immunol 146: 1972-1978. PubMed: 2005388.
22. Mbawuike IN, Pacheco S, Acuna CL, Switzer KC, Zhang Y et al. (1999) Mucosal Immunity to Influenza Without IgA: An IgA Knockout Mouse Model. J Immunol 162: 2530-2537. PubMed: 10072492.
23. Wrammert J, Koutsonanos D, Li G-M, Edupuganti S, Sui J et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208: 181-193. doi:10.1084/jem.20101352. PubMed: 21220454.
24. Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S et al. (2013) 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis 207: 98-105. doi:10.1093/infdis/jis652. PubMed: 23087428.
25. Wrammert J, Smith K, Miller J, Langley WA, Kokko K et al. (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453: 667-671. doi:10.1038/nature06890. PubMed: 18449194.